Zealand CEO sees competitive advantage over Novo
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article7575831.ece/ALTERNATES/schema-16_9/Britt%2520Meelby%2520Jensen2.jpg)
The risks have been minimized and the potential is great. That is the overall reaction from Zealand Pharma’s CEO, Britt Meelby Jensen, after the biotech’s French partner, Sanofi, announced positive phase III data from the two companies’ combination drug LixiLan this week.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Novo’s product is superior, but…
For abonnenter
Zealand CEO: We are obligated to be ambitious
For abonnenter
Zealand chief is pleased with quiet quarter
For abonnenter